XML 40 R27.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) | 6 Months Ended
--- | ---
Dec. 31, 2021
Notes Tables |
Schedule of Stockholders Equity [Table Text Block] |
|  | Bio-Techne Shareholders |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | Additional |  |  |  |  |  |  | Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Retained |  |  | Comprehensive |  |  | Noncontrolling |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Earnings |  |  | Income(Loss) |  |  | Interest |  |  | Total |
Balances at June 30, 2021 |  |  | 38,955 |  |  | $ | 390 |  |  | $ | 534,411 |  |  | $ | 1,085,461 |  |  | $ | (57,291 | ) |  | $ | 8,263 |  |  | $ | 1,571,234 |
Net earnings |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 69,615 |  |  |  |  |  |  |  | (634 | ) |  |  | 68,981 |
Other comprehensive income (loss) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (6,925 | ) |  |  | (39 | ) |  |  | (6,964 | )
Share repurchases |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued for exercise of options |  |  | 295 |  |  |  | 3 |  |  |  | 36,345 |  |  |  | (13,481 | ) |  |  |  |  |  |  |  |  |  |  | 22,867 |
Common stock issued for restricted stock awards |  |  | 20 |  |  |  | 0 |  |  |  | 0 |  |  |  | (9,765 | ) |  |  |  |  |  |  |  |  |  |  | (9,765 | )
Cash dividends |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (12,493 | ) |  |  |  |  |  |  |  |  |  |  | (12,493 | )
Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  | 11,396 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,396 |
Common stock issued to employee stock purchase plan |  |  | 3 |  |  |  | 0 |  |  |  | 1,358 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,358 |
Employee stock purchase plan expense |  |  |  |  |  |  |  |  |  |  | 341 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 341 |
Balances at September 30, 2021 |  |  | 39,273 |  |  | $ | 393 |  |  | $ | 583,851 |  |  | $ | 1,119,337 |  |  | $ | (64,216 | ) |  | $ | 7,590 |  |  | $ | 1,646,955 |
Net earnings |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 80,173 |  |  |  |  |  |  |  | (8,114 | ) |  |  | 72,059 |
Other comprehensive income (loss) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,742 |  |  |  | 66 |  |  |  | 4,808 |
Share repurchases |  |  | (89 | ) |  |  | (1 | ) |  |  |  |  |  |  | (41,293 | ) |  |  |  |  |  |  |  |  |  |  | (41,294 | )
Common stock issued for exercise of options |  |  | 134 |  |  |  | 1 |  |  |  | 18,604 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,605 |
Common stock issued for restricted stock awards |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash dividends |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (12,576 | ) |  |  |  |  |  |  |  |  |  |  | (12,576 | )
Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  | 13,701 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,701 |
Common stock issued to employee stock purchase plan |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 |
Employee stock purchase plan expense |  |  |  |  |  |  |  |  |  |  | 267 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 267 |
Balances at December 31, 2021 |  |  | 39,319 |  |  |  | 393 |  |  |  | 616,429 |  |  |  | 1,145,641 |  |  |  | (59,474 | ) |  |  | (458 | ) |  |  | 1,702,531 |
|  | Bio-Techne Shareholders |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | Additional |  |  |  |  |  |  | Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Retained |  |  | Comprehensive |  |  | Noncontrolling |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Earnings |  |  | Income(Loss) |  |  | Interest |  |  | Total |
Balances at June 30, 2020 |  |  | 38,453 |  |  | $ | 385 |  |  | $ | 420,536 |  |  | $ | 1,057,470 |  |  | $ | (97,199 | ) |  | $ | - |  |  | $ | 1,381,192 |
Cumulative effect adjustments due to adoption of new accounting standards |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (276 | ) |  |  |  |  |  |  |  |  |  |  | (276 | )
Net earnings |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 33,395 |  |  |  |  |  |  |  |  |  |  |  | 33,395 |
Other comprehensive income (loss) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,057 |  |  |  |  |  |  |  | 14,057 |
Common stock issued for exercise of options |  |  | 117 |  |  |  | 1 |  |  |  | 13,727 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,728 |
Common stock issued for restricted stock awards |  |  | 25 |  |  |  | 0 |  |  |  | (0 | ) |  |  | (4,890 | ) |  |  |  |  |  |  |  |  |  |  | (4,890 | )
Cash dividends |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (12,336 | ) |  |  |  |  |  |  |  |  |  |  | (12,336 | )
Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  | 12,667 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,667 |
Common stock issued to employee stock purchase plan |  |  | 6 |  |  |  | 0 |  |  |  | 1,463 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,463 |
Employee stock purchase plan expense |  |  |  |  |  |  |  |  |  |  | 286 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 286 |
Balances at September 30, 2020 |  |  | 38,601 |  |  | $ | 386 |  |  | $ | 448,679 |  |  | $ | 1,073,362 |  |  | $ | (83,142 | ) |  | $ | - |  |  | $ | 1,439,285 |
Non-controlling interest in Eminence |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,985 |  |  |  | 8,985 |
Net earnings |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 46,274 |  |  |  |  |  |  |  | (130 | ) |  |  | 46,144 |
Other comprehensive income (loss) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,904 |  |  |  | 83 |  |  |  | 18,987 |
Common stock issued for exercise of options |  |  | 161 |  |  |  | 2 |  |  |  | 16,748 |  |  |  | (2,482 | ) |  |  |  |  |  |  |  |  |  |  | 14,268 |
Common stock issued for restricted stock awards |  |  | 3 |  |  |  | 0 |  |  |  | (0 | ) |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  | 0 |
Cash dividends |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (12,392 | ) |  |  |  |  |  |  |  |  |  |  | (12,392 | )
Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  | 15,471 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,471 |
Employee stock purchase plan expense |  |  |  |  |  |  |  |  |  |  | 106 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 106 |
Balances at December 31, 2020 |  |  | 38,765 |  |  | $ | 388 |  |  | $ | 481,004 |  |  | $ | 1,104,762 |  |  | $ | (64,238 | ) |  | $ | 8,938 |  |  | $ | 1,530,854 |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] |
|  | Unrealized Gains (Losses) on Derivative Instruments |  |  | Foreign Currency Translation Adjustments |  |  | Total |
Balance as of June 30, 2021 |  | $ | (6,193 | ) |  | $ | (51,098 | ) |  | $ | (57,291 | )
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne |  |  | 1,682 |  |  |  | (6,750 | ) |  |  | (5,068 | )
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) |  |  | 2,884 |  |  | $ | - |  |  | $ | 2,884 |
Balance as of December 31, 2021(2) |  | $ | (1,626 | ) |  |  | (57,848 | ) |  |  | (59,474 | )
|  | Unrealized Gains (Losses) on Derivative Instruments |  |  | Foreign Currency Translation Adjustments |  |  | Total |
Balance as of June 30, 2020 attributable to Bio-Techne |  | $ | (13,253 | ) |  | $ | (83,946 | ) |  | $ | (97,199 | )
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne |  |  | (47 | ) |  |  | 28,759 |  |  |  | 28,712 |
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3) |  |  | 4,249 |  |  |  | - |  |  |  | 4,249 |
Balance as of December 31, 2020(2) |  | $ | (9,051 | ) |  | $ | (55,187 | ) |  | $ | (64,238 | )

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration